ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Kansas City, KS

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Epithelial Carcinoma

Triple Negative Breast Cancer trials near Kansas City, KS, USA:

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT)

The standard treatment for women with stage I, II, and III triple-negative breast cancer (TNBC) includes chemothe ...

Active, not recruiting
Triple-negative Breast Cancer
Drug: Pegfilgrastim
Drug: Carboplatin

Phase 2

University of Kansas
University of Kansas

Kansas City, Kansas, United States and 8 other locations

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Study combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNB ...

Active, not recruiting
Breast Cancer
Triple-Negative Breast Cancer
Drug: Cisplatin
Drug: Romidepsin

Phase 1, Phase 2

Priyanka Sharma

Kansas City, Kansas, United States and 6 other locations

Locations recently updated

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen rec...

Begins enrollment in 2 months
Breast Neoplasms
Drug: Paclitaxel
Drug: Iza-bren

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Kansas City, Missouri, United States and 217 other locations

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Kansas City, Kansas, United States and 516 other locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Kansas City, Kansas, United States and 505 other locations

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Active, not recruiting
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Westwood, Kansas, United States and 275 other locations

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CAPItello-290)

III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Placebo

Phase 3

AstraZeneca
AstraZeneca

Westwood, Kansas, United States and 257 other locations

Recently updated

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors...

Enrolling
Uterine Cancer
Hormone Receptor-positive/Her2 Negative Breast Cancer
Drug: Carboplatin
Drug: Pembrolizumab

Phase 1, Phase 2

Genmab
Genmab

Westwood, Kansas, United States and 36 other locations

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), end...

Active, not recruiting
Castration-resistant Prostate Cancer
Lower Esophageal Cancer
Drug: cabozantinib
Drug: atezolizumab

Phase 1, Phase 2

Exelixis
Exelixis

Kansas City, Missouri, United States and 123 other locations

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs ...

Enrolling
HER2 Positive Breast Neoplasms
HER2 Low Breast Neoplasms
Drug: disitamab vedotin
Drug: tucatinib

Phase 2

Seagen, a wholly owned subsidiary of Pfizer

Kansas City, Missouri, United States and 121 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems